This website is intended for healthcare professionals only

Trending Topic

16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]

Jean Claude Tardif, AHA 2019 – Results from the COLCOT trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 12th 2019

Jean-Claude Tardif (Director of the Research Centre, Montreal Heart Institute and Professor of Medicine, University of Montreal, Montreal, QC, Canada) reviews the results from the COLchicine Cardiovascular Outcomes Trial (COLCOT), presented at the American Heart Association (AHA) Scientific Sessions 2019.

Speaker’s Disclosures: Dr. Tardif reports grants from Government of Quebec; grants from Amarin, grants and personal fees from Astra Zeneca, grants, personal fees and other from DalCor, grants from Esperion, grants from Ionis, grants and personal fees from Pfizer, grants and personal fees from Sanofi, grants and personal fees from Servier.

touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup